NanoPass Technologies Ltd. is a pioneer in the development and commercialization of nearly painless intradermal delivery solutions for vaccines and drugs. Its flagship product, the 0.6mm MicronJet600 microneedle, is the first and only true (<1mm) microneedle to receive FDA clearance as an intradermal delivery device for substances approved for delivery below the surface of the skin. It has proven its efficacy in vaccination delivery with improved potency, immunogenicity and dose sparing1-8,10.
Supported by extensive clinical data and regulatory approvals in leading markets, NanoPass is ready to expand its reach by partnering with pharma companies aiming to provide better patient care worldwide.
The company supports multiple phase I-III clinical studies and is actively pursuing additional partnerships with vaccine developers worldwide.
Ornit Zeltzer - Regulatory Affairs Director
Originally joined NanoPass on May 2007, establishing its certified quality system and compiling regulatory files to support product CE certification and FDA clearance, rejoined NanoPass on January 2015. Ornit has over 10 years of regulatory affairs and quality assurance experience in the Medical Devices (Colbar life Science Ltd., acquired by J&J) as well as pharmaceutical (Teva Pharmaceuticals Ltd.) and Biopharmaceuticals (Omrix Biopharmaceutical Ltd., acquired by J&J) arenas.
Ornit holds a B.Sc. in chemistry from Tel-Aviv university and Ms.C. in quality assurance and reliability from Technion Israel Institute of echnology.
Gal Demer - R&D Director
Gal Demer joined Nanopass Technologies Ltd. In February 2016 as R&D director and is in charge of the company’s engineering and development activities. Gal has over 15 years of experience in mechanical engineering, project and R&D management, mainly of medical devices in the fields of vascular implants, minimally invasive devices, mechanical ventilation, rehabilitation and diagnostic devices. Gal has a B.Sc. in Mechanical engineering from Tel Aviv University and worked for Mindguard Ltd., R.M.T Ltd., GE Healthcare (Versamed Ltd.), Itamar Medical Ltd., and Landa Corporation Ltd.
Gal Admati - COO
Gal Admati joined Nanopass Technologies Ltd. In 2012. Gal is NanoPass’s COO and oversees daily activities including production, operations, R&D, quality, regulation and administration. Gal joined NanoPass as R&D director and was in charge of the company’s research and development activities as well as the company’s engineering activities and device manufacturing processes. Gal has experience in management, medical device research and development, machining, design, micro mechanics and mechanical automation. Gal has a B.Sc. in biomedical engineering and an MBA with a specialization in Strategy from Tel Aviv University.
Dr. Yotam Levin - CEO
Dr. Yotam Levin has been the CEO of NanoPass Technologies Ltd. since 2002. He is in charge of the Company’s strategy, business development and all clinical activities. Under his supervision the company successfully licensed its product with the FDA and the European authorities, and conducted pioneering intradermal vaccination studies. Prior to becoming CEO at NanoPass, Dr Levin was head of the biomedical consulting practice at Global Business Solutions, an Israeli strategic consulting firm. Dr Levin holds an MD degree and an MBA (finance), both from Tel Aviv University, Israel. Dr Levin authored several key publications in leading journals such as the Lancet Infectious Diseases, Vaccine, JID and HV&I, and participated in authoring over two-dozen patent applications. He serves as a frequent reviewer for Vaccine, Journal of Infectious diseases (JID) and Human Vaccines & Immunotherapeutics (HV&I), and was a Guest Editor for Vaccine’s Skin Vaccination Summit 2015. In his spare time, he runs marathons, teaches biomedical entrepreneurship and volunteers with a disabled children NPO.
Dr. Efrat Kochba - Medical Director
Dr. Efrat Kochba joined NanoPass Technologies Ltd. in 2012 as medical director and is in charge of managing the clinical activities of the company, as well as business development and marketing activities. Dr. Kochba brings a wide experience in the field of drug delivery working for TransPharma Medical Ltd., a company that focused on transdermal drug delivery. Efrat holds an MD degree from the Hebrew university in Jerusalem and practiced ENT medicine for six years prior to joining Roche pharmaceuticals as a medical and clinical trials manager.
Eric Resnick - Director
Mr. Eric Resnick has been Chief Technology Officer and Vice President at West Pharmaceutical Services, Inc. since April 1, 2016. Mr. Resnick is responsible for leading West’s Innovation and Technology Team, which has been established to identify and develop the next generation of packaging, containment, and drug delivery products, processes and services. Mr. Resnick previously held a number of leadership roles within West, including Vice President & General Manager, Integrated Packaging & Delivery, as well as Vice President and General Manager of West’s Contract Manufacturing Drug Delivery Device business unit in Tempe, AZ. Prior to joining West, Mr. Resnick held engineering and operating roles with Eastman Kodak and Ortho Clinical Diagnostics. He is a certified Six Sigma Black Belt with a BS in Plastics Engineering from the University of Massachusetts Lowell and an MBA from the University of Phoenix.
Marvin Samson - Director
Mr. Samson, founder and CEO of Samson Medical Technologies and Chairman of the Board of Trustees of the University of the Sciences, was formerly a Group Vice President – Worldwide Injectables of Teva, previously having served as CEO and a member of the Board of Directors of Sicor (acquired in 2004 by Teva for $3.4 billion). He was also the CEO of Qualitest Pharmaceuticals. He is an expert in injectable manufacturing and delivery systems and was a founder and CEO of Elkins-Sinn (today, West-Ward Pharmaceuticals, one of the largest generic injectables companies in the U.S.) and Marsam Pharmaceuticals.
Dr. Hadar Ron - Director
Dr. Ron is a physician and attorney. She has extensive medical, legal and management experience in insurance companies, law firms, medical and educational institutions. Her legal and management expertise includes venture capital consulting, medical malpractice, general and medical insurance and legal practice. Hadar holds an MD from the Sackler School of Medicine, Tel Aviv University, and an LL.B. in Law from Tel Aviv University.
Ehud Raivitz - Director
Ehud Raivitz was until recently the CEO of Elcam Medical ACS Ltd., a leading worldwide OEM supplier, servicing the medical industry in the area of Fluid Management, Vital Signs Monitoring and Drug Delivery, and the chairman of Elcam Medical US. Ehud received a bachelor’s degree in mechanical engineering from the Technion and an MBA from Tel Aviv University.
Ilan Neugarten - Director
Ilan Neugarten joined the Viola Partners Group in 2000 as a partner of DOR Ventures, a VC fund focusing on imaging technologies. During his period at DOR Ventures he led various investments including medical imaging ventures. Since 2006 he leads the healthcare investments of VPartners, and currently serves on the boards of Angioslide, EndoCross and PainReform. Prior to joining the Viola Partners Group he worked for Scitex ( NASDAQ:SCIX ) in various management positions in Europe, Japan, and Israel. He received his B.Sc. in electronics from the Technion and MBA from Boston University.
Yoav Sebba - Director
Yoav Sebba acts as Vice President at XT Investments from 2006. Yoav serves as a board member in ZIM Integrated Shipping Services, NanoPass, CorAssist, IntraTech, Angioslide and EndoCross. Yoav served as a board member in Cognitens (acquired by Hexagon), Kailight (acquired by Optium), Impactia (acquired by eWave), Applied Spectral Imaging, Tevet (acquired by NanoMetris), Yadata (acquired by Microsoft) & Next9. Prior to joining XT Investments Yoav acted as a partner at Yozma Venture Capital (which is part of the XT Investments portfolio) from 1998. Prior to joining Yozma Yoav acted as a project manager at Bank Leumi. Yoav holds a B.Sc. in Industrial Engineering and Management, with distinction, from the Technion Institute of Technology, and an MBA from the Haifa University.
Dr. Shuki Yeshurun - Founder
Dr. Yeshurun brings two decades of MEMS and advanced materials R&D expertise to NanoPass. His work integrates both commercial and academic experience. Dr. Yeshurun has an established history in bringing multi-million dollar technology-intensive projects from a concept to the market. Dr. Yeshurun earned his B.Sc. in Mechanical engineering at the Beer Sheva University, and his M.Sc. and PhD in Advanced Materials at the Technion Institute of Technology. A prolific scholar, Dr. Yeshurun has authored over 40 professional publications and 50 classified reports. He is a lecturer at the Technion Institute. A Senior Scientist at NATIONAL LAB, Dr. Yeshurun was a group leader in charge of developing piezoelectric materials for MEMS applications. Dr. Yeshurun holds over a dozen patents and was awarded the American Ceramic Society “Rose” Award for his work. He serves as member of the Board of Directors.
NanoPass has strategic relationships with:
- West Pharmaceutical Services
- Circassia, Oxford: first in class novel allergy vaccines
- Immune Design, San- Francisco: cancer immunotherapy
- Infectious Diseases Research Institute, Seattle: Global health vaccines (Tubeculosis, pandemic flu)
- EE-ASI: A European consortium developing novel T1DM immunotherapy